Delta-9 THC (Delta-9-tetrahydrocannabinol) is no longer just “marijuana”—it is now federally recognized as a Schedule III substance with accepted medical value. This shift, finalized following a late 2025 Executive Order, has completely restructured the legal, tax, and research landscape for the industry.